TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Cornerstone Wealth Management LLC

Cornerstone Wealth Management LLC lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 68.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,247 shares of the company's stock after purchasing an additional 2,540 shares during the quarter. Cornerstone Wealth Management LLC's holdings in TransMedics Group were worth $420,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. NBC Securities Inc. acquired a new position in TransMedics Group in the 1st quarter worth about $25,000. Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group in the fourth quarter valued at approximately $31,000. AlphaQuest LLC purchased a new stake in shares of TransMedics Group in the fourth quarter valued at approximately $52,000. Arcadia Investment Management Corp MI acquired a new position in TransMedics Group during the fourth quarter worth $72,000. Finally, Rakuten Securities Inc. raised its position in shares of TransMedics Group by 68.3% during the 4th quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock worth $84,000 after purchasing an additional 550 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the sale, the director now owns 732 shares in the company, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider now directly owns 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,418 shares of company stock worth $1,512,613. Company insiders own 7.00% of the company's stock.

Analyst Ratings Changes

TMDX has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Oppenheimer raised their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $127.33.

TransMedics Group Trading Up 4.0%

Shares of TMDX stock traded up $5.11 during trading on Tuesday, hitting $132.64. 734,049 shares of the stock traded hands, compared to its average volume of 1,364,571. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The firm has a market capitalization of $4.49 billion, a P/E ratio of 97.53 and a beta of 2.10. The firm's fifty day moving average price is $115.04 and its 200-day moving average price is $84.67. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The company had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. During the same quarter last year, the firm earned $0.35 earnings per share. The firm's quarterly revenue was up 48.2% compared to the same quarter last year. As a group, research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.